CN115040550A - 一种用于提高免疫球蛋白g的组合物 - Google Patents
一种用于提高免疫球蛋白g的组合物 Download PDFInfo
- Publication number
- CN115040550A CN115040550A CN202210641032.4A CN202210641032A CN115040550A CN 115040550 A CN115040550 A CN 115040550A CN 202210641032 A CN202210641032 A CN 202210641032A CN 115040550 A CN115040550 A CN 115040550A
- Authority
- CN
- China
- Prior art keywords
- beta
- composition
- methylbutyrate
- hydroxy
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940027941 immunoglobulin g Drugs 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 230000001965 increasing effect Effects 0.000 title claims description 11
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000006041 probiotic Substances 0.000 claims abstract description 20
- 235000018291 probiotics Nutrition 0.000 claims abstract description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 13
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004475 Arginine Substances 0.000 claims abstract description 12
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims description 6
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 6
- 230000000529 probiotic effect Effects 0.000 claims description 6
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- 241000193749 Bacillus coagulans Species 0.000 claims description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 4
- 229940054340 bacillus coagulans Drugs 0.000 claims description 4
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 230000035899 viability Effects 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 abstract description 15
- 206010028980 Neoplasm Diseases 0.000 abstract description 10
- 241000699670 Mus sp. Species 0.000 abstract description 9
- 201000007270 liver cancer Diseases 0.000 abstract description 7
- 208000014018 liver neoplasm Diseases 0.000 abstract description 7
- 235000013305 food Nutrition 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 229940127554 medical product Drugs 0.000 abstract description 2
- 229960004316 cisplatin Drugs 0.000 description 13
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 6
- 239000002994 raw material Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- ZSTCHQOKNUXHLZ-PIRIXANTSA-L [(1r,2r)-2-azanidylcyclohexyl]azanide;oxalate;pentyl n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate;platinum(4+) Chemical compound [Pt+4].[O-]C(=O)C([O-])=O.[NH-][C@@H]1CCCC[C@H]1[NH-].C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 ZSTCHQOKNUXHLZ-PIRIXANTSA-L 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940105442 cisplatin injection Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/517—Bifidum
Abstract
本发明公开了一种用于提高免疫球蛋白G的组合物，属于医药或食品技术领域。本发明公开的一种用于提高免疫球蛋白G的组合物，由以下组分组成：β‑羟基‑β‑甲基丁酸盐0.01‑0.53份、益生菌0.01‑98份、谷氨酰胺0.7‑10.7份、亮氨酸0.5‑98份、精氨酸2.3‑98份。本发明的组合物通过协调作用，可以提高肝癌小鼠化疗后免疫球蛋白G含量，能够应用在特殊医学用途肿瘤配方食品或医药产品中，对提高化疗后抗肿瘤有着重要的意义。
Description
技术领域
本发明涉及医药或食品技术领域，更具体的说是涉及一种用于提高免疫球蛋白G的组合物。
背景技术
肿瘤可分为良性肿瘤和恶性肿瘤。恶性肿瘤又被称为癌症，其增长迅速，具有侵袭性(向周围组织浸润)和转移性，如未经有效治疗，通常导致死亡。对国内肿瘤患者的营养风险及营养不良研究现状分析发现，在我国恶性肿瘤患者中，营养风险发生率较高。合理、有效的营养支持可明显提高肿瘤患者术后营养和免疫状况，减少术后并发症和感染的发生，提高患者救治率、降低病死率，降低医疗负担，对大部分营养不良肿瘤患者具有积极意义。
β-羟基-β-甲基丁酸盐(HMB)具有促进肌肉蛋白合成、抑制肌肉蛋白分解、稳定肌纤维膜和增强肌肉再生能力、改善肌肉质量和功能等作用。HMB对顺铂化疗后免疫球蛋白G(IgG)的相关研究并未报道。
益生菌是一类对宿主有益的活性微生物，它在维持宿主微生态平衡、改善人类健康中发挥积极作用。目前已有多种益生菌被允许用于食品中，如嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌、两歧双歧杆菌等。益生菌对人体免疫功能及炎症反应的影响，对癌患者术后免疫功能及炎症反应的影响，均有相关报道。由于化疗的药物不同，对IgG的影响不同。相关研究人员报告，采用XELOX化疗方案进行化疗，或奥沙利铂对照组的基础上口服益生菌对人体免疫力指标的影响，但并未报道顺铂化疗的相关研究，在其它文献及专利检索均未发现对顺铂化疗后食用益生菌对IgG影响的相关报道。由于化疗药物及实验目标不同，对结果的影响也会不同，因此没有参考意义。
谷氨酰胺是一种条件必需氨基酸。已有多项基础研究表明补充外源性谷氨酰胺，可以通过调控生长因子和细胞因子来增强巨噬细胞吞噬和NK细胞直接杀伤肿瘤细胞毒效应，显著改善免疫效能。亮氨酸已有的研究结果显示，采用运动与补充亮氨酸进行联合干预可以有效促进蛋白质周转并提升机体氮含量，但其对机体炎性反应的影响则仍未阐明。对顺铂化疗后食用亮氨酸对肝癌的免疫球蛋白G的相关研究并未发现。精氨酸作为一种特殊的免疫调节因子在肿瘤治疗中备受重视，它是合成一氧化氮的唯一底物，可以促进蛋白质合成、改善机体免疫功能、促进淋巴细胞增殖和分化、维护肠黏膜完整性、促进伤口愈合、降低感染发生率等。但食用精氨酸在顺铂化疗后对肝癌免疫球蛋白G的相关研究并未报道。
因此，提供一种用于提高免疫球蛋白G的组合物是本领域技术人员亟需解决的问题。
发明内容
有鉴于此，本发明提供了一种用于提高免疫球蛋白G的组合物，主要针对肿瘤负荷者的特点，经过多次实验研究发现将β-羟基-β-甲基丁酸盐、益生菌、谷氨酰胺、亮氨酸、精氨酸的组合物通过配方比例调整及配方优化，能够有效改善肝癌顺铂化疗后免疫球蛋白G的指标。
为了实现上述目的，本发明采用如下技术方案：
一种用于提高免疫球蛋白G的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.01-0.53份、益生菌0.01-98份、谷氨酰胺0.7-10.7份、亮氨酸0.5-98份、精氨酸2.3-98份。
进一步，所述β-羟基-β-甲基丁酸盐选自β-羟基-β-甲基丁酸钙、β-羟基-β-甲基丁酸钠、β-羟基-β-甲基丁酸钾中的至少一种。
进一步，所述益生菌的活力单位为106-1014CFU/g；所述益生菌选自凝结芽孢杆菌、两歧双歧杆菌、嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌中的至少一种。
进一步，一种用于提高免疫球蛋白G的组合物的制备方法，包括如下步骤：
(1)将所述原料过30目筛；
(2)将步骤(1)过筛后的原料在混料机中混合30分钟。
经由上述的技术方案可知，与现有技术相比，本发明公开提供了一种用于提高免疫球蛋白G的组合物，由β-羟基-β-甲基丁酸盐、益生菌、谷氨酰胺、亮氨酸、精氨酸组成，该组合物通过协调作用，可以提高肝癌小鼠化疗后免疫球蛋白G含量，能够应用在特殊医学用途肿瘤配方食品或医药产品中，对提高化疗后抗肿瘤有着重要的意义。
具体实施方式
下面将对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
凝结芽孢杆菌、两歧双歧杆菌、嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌均为市售菌株。
实施例1
一种用于提高免疫球蛋白G的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.53g、益生菌98g、谷氨酰胺10.7g、亮氨酸98g、精氨酸98g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钙。
益生菌选自副干酪乳杆菌，活力单位为1014CFU/g。
上述用于提高免疫球蛋白G的组合物的制备方法，包括如下步骤：
(1)将上述原料过30目筛；
(2)将步骤(1)过筛后的原料在混料机中混合30分钟。
实施例2
一种用于提高免疫球蛋白G的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.01g、益生菌0.01g、谷氨酰胺0.7g、亮氨酸0.5g、精氨酸2.3g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钠。
益生菌选自罗伊氏乳杆菌，活力单位为106CFU/g。
上述用于提高免疫球蛋白G的组合物的制备方法同实施例1。
实施例3
一种用于提高免疫球蛋白G的组合物，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.23g、益生菌5g、谷氨酰胺5g、亮氨酸30g、精氨酸35g。
β-羟基-β-甲基丁酸盐为β-羟基-β-甲基丁酸钾。
益生菌选自副干酪乳杆菌(活力单位为108CFU/g)2g和凝结芽孢杆菌(活力单位为108CFU/g)3g。
上述用于提高免疫球蛋白G的组合物的制备方法同实施例1。
对比例1
将谷氨酰胺5g，与北京科奥协力饲料有限公司的大小鼠维持饲料70.23g混合制备对比例1样品。
制备方法同实施例1。
对比例2
将精氨酸35g，与北京科奥协力饲料有限公司的大小鼠维持饲料40.23g混合制备对比例2样品。
制备方法同实施例1。
对比例3
将北京科奥协力饲料有限公司的大小鼠维持饲料作为对比例3样品。
制备方法同实施例1。
选择SPF级KM小鼠30只，接种肝癌H22细胞，雌雄各半，体重为18g-22g。环境温度为20℃-26℃，湿度为40％-70％，待负荷瘤成功生长形成。小鼠分为实施例1样品组、实施例2样品组、实施例3样品组、对比例1样品组、对比例2样品组、对比例3样品组(模型组)，每组各5只。第1-16天，每天每组小鼠分别按组喂食10g/kg.BW制备的样品1次，并第4天注射顺铂溶液1次及第11天注射顺铂溶液1次(顺铂溶液：将5mg/mL顺铂注射液用生理盐水配成2.5mg/mL顺铂溶液；第4天和第11天的注射剂量均为2.4mL/kg)，第16天，取外周血，加入抗凝剂，离心，取上清，置-80℃冰箱备用。
各组小鼠血清中每只小鼠IgG的含量(ng/ml)结果如下：
各组小鼠血清中IgG的平均含量(ng/ml)如下：
上述结果表明，实施例1样品组与对比例1、2、3样品组比较，IgG分别提高40.50％，36.49％，32.68％；实施例2样品组与对比例1、2、3样品组比较，IgG分别提高55.04％，50.62％，46.41％；实施例3样品组与对比例1、2、3样品组比较，IgG分别提高76.04％，71.02％，66.24％。
查阅专利及文献发现，膳食中添加β-羟基-β-甲基丁酸盐对顺铂化疗后提高IgG相关研究并未曾报道，因此，本发明不用β-羟基-β-甲基丁酸盐、亮氨酸制样做对比实验，同时，以谷氨酰胺、精氨酸为主要原料制样喂食及顺铂模型组分别做对比实验，发现本发明组合物均能提高肝癌顺铂化疗后小鼠血清中免疫球蛋白G(IgG)的含量。
因此，本发明组分可以添加在特医食品或药品组分中，可提高机体免疫力，同时具有实用性。
对所公开的实施例的上述说明，使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的，本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下，在其它实施例中实现。因此，本发明将不会被限制于本文所示的这些实施例，而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (3)
1.一种用于提高免疫球蛋白G的组合物，其特征在于，按重量份计，由以下组分组成：β-羟基-β-甲基丁酸盐0.01-0.53份、益生菌0.01-98份、谷氨酰胺0.7-10.7份、亮氨酸0.5-98份、精氨酸2.3-98份。
2.根据权利要求1所述的一种用于提高免疫球蛋白G的组合物，其特征在于，所述β-羟基-β-甲基丁酸盐选自β-羟基-β-甲基丁酸钙、β-羟基-β-甲基丁酸钠、β-羟基-β-甲基丁酸钾中的至少一种。
3.根据权利要求1所述的一种用于提高免疫球蛋白G的组合物，其特征在于，所述益生菌的活力单位为106-1014CFU/g；所述益生菌选自凝结芽孢杆菌、两歧双歧杆菌、嗜酸乳杆菌、鼠李糖乳杆菌、罗伊氏乳杆菌、副干酪乳杆菌中的至少一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210641032.4A CN115040550A (zh) | 2022-06-07 | 2022-06-07 | 一种用于提高免疫球蛋白g的组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210641032.4A CN115040550A (zh) | 2022-06-07 | 2022-06-07 | 一种用于提高免疫球蛋白g的组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115040550A true CN115040550A (zh) | 2022-09-13 |
Family
ID=83162019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210641032.4A Pending CN115040550A (zh) | 2022-06-07 | 2022-06-07 | 一种用于提高免疫球蛋白g的组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115040550A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810238A (zh) * | 2005-01-24 | 2006-08-02 | 姜广良 | 精氨酸口服配方预防和治疗恶液质综合症 |
| CN104302285A (zh) * | 2012-01-11 | 2015-01-21 | 雅培制药有限公司 | 用于治疗糖尿病性溃疡的β-羟基-β-甲基丁酸盐、精氨酸和谷氨酰胺的组合产品 |
| CN105395567A (zh) * | 2014-09-10 | 2016-03-16 | 宝耕生技股份有限公司 | 减缓化疗药物副作用的组合物 |
| CN111436601A (zh) * | 2020-05-11 | 2020-07-24 | 上海复旦奥医医学科技有限公司 | 一种胰腺癌专用型临床营养配方及其制备 |
| CN113615837A (zh) * | 2021-07-30 | 2021-11-09 | 珍奥集团股份有限公司 | 一种延缓衰老的核苷酸益生菌胶囊 |
-
2022
- 2022-06-07 CN CN202210641032.4A patent/CN115040550A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1810238A (zh) * | 2005-01-24 | 2006-08-02 | 姜广良 | 精氨酸口服配方预防和治疗恶液质综合症 |
| CN104302285A (zh) * | 2012-01-11 | 2015-01-21 | 雅培制药有限公司 | 用于治疗糖尿病性溃疡的β-羟基-β-甲基丁酸盐、精氨酸和谷氨酰胺的组合产品 |
| CN105395567A (zh) * | 2014-09-10 | 2016-03-16 | 宝耕生技股份有限公司 | 减缓化疗药物副作用的组合物 |
| CN111436601A (zh) * | 2020-05-11 | 2020-07-24 | 上海复旦奥医医学科技有限公司 | 一种胰腺癌专用型临床营养配方及其制备 |
| CN113615837A (zh) * | 2021-07-30 | 2021-11-09 | 珍奥集团股份有限公司 | 一种延缓衰老的核苷酸益生菌胶囊 |
Non-Patent Citations (4)
| Title |
|---|
| OSTASZEWSKI, PIOTR ET AL.: "3-hydroxy-3-methylbutyric acid (HMB) in immunological reactions generated by nutritional allergy in guinea pigs", 《MEDYCYNA WETERYNARYJNA-VETERINARY MEDICINE-SCIENCE AND PRACTICE》, pages 100 - 102 * |
| TOMOYA YOKOTA ET AL.: "A phase II study of HMB/Arg/Gln against oral mucositis induced by chemoradiotherapy for patients with head and neck cancer", 《SUPPORTIVE CARE IN CANCER》, pages 1 - 8 * |
| 纪俊标 等: "应用肠内免疫营养与生态营养对胃癌术后患者营养支持疗效的前瞻、随机、对照临床研究", 《南京医科大学学报（自然科学版）》, pages 338 - 344 * |
| 郭俊清 等: "过瘤胃包被亮氨酸及β－羟基－β－甲基丁酸钙对内蒙古白绒山羊免疫机能的影响", 《动物营养学报》, pages 1762 - 1767 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yazdi et al. | The preventive oral supplementation of a selenium nanoparticle-enriched probiotic increases the immune response and lifespan of 4T1 breast cancer bearing mice | |
| KR101677516B1 (ko) | 락토바실러스 루테리 블랙8, 및 이를 함유하는 항종양 조성물 | |
| CN115414390A (zh) | 具有改善肠道微生态性能和增强肿瘤免疫检查点抑制剂治疗效果的益生菌复合制剂及应用 | |
| CN112587637B (zh) | 一种具有增强免疫功能的多效益生菌制剂及其应用 | |
| CN115040550A (zh) | 一种用于提高免疫球蛋白g的组合物 | |
| CN115067518A (zh) | 一种用于提高肿瘤患者免疫力的组合物 | |
| JP5209294B2 (ja) | インターロイキン１２産生促進剤 | |
| CN104642732B (zh) | 一种肉鸭饲料添加剂及其应用 | |
| JPWO2019240218A1 (ja) | 免疫チェックポイント阻害療法を促進するための組成物 | |
| CN115851542A (zh) | 一株以d-阿洛酮糖为碳源的凝结芽孢杆菌菌株及其衍生产品和应用 | |
| CN112915110B (zh) | 一种纤体养颜益生菌制剂及其制备方法与应用 | |
| JP5088817B2 (ja) | 乳酸菌とシソ科の植物とを含む組成物 | |
| CN110638842A (zh) | 一种改善高血糖的益生菌组合物 | |
| JP4064515B2 (ja) | Ｉｌ−１２産生誘導組成物 | |
| CN110279720B (zh) | 一种五谷虫炮制品及其在调节肠道菌群中的应用 | |
| JPH0892112A (ja) | サイトカイン産生促進剤 | |
| CN115040549A (zh) | 一种用于肿瘤的组合物 | |
| CN101665800B (zh) | 一种微生态制剂的制备方法及其用途 | |
| CN113133531A (zh) | 一种复合蛋白补充剂及其制备方法 | |
| CN111567809A (zh) | 具有提高免疫力和调节肠道功能的动物双歧杆菌bz11复合菌剂 | |
| JP5717224B1 (ja) | 粉末状の機能性食品及びその製造方法 | |
| CN114164148B (zh) | 一株马乳酒样乳杆菌、菌剂及其应用 | |
| Kamal et al. | Combination of ketogenic diet and probiotics inhibits breast cancer in mice by immune system modulation and reduction of Insulin growth factor-1 | |
| CN115433703B (zh) | 辣椒碱在促进嗜粘蛋白阿克曼氏菌增殖中的应用 | |
| CN114806920B (zh) | 一种双歧杆菌的培养基及其培养方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220913 |